Xeris Pharmaceuticals
Update in progressXERS (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological diseases. Based in Chicago, Illinois, it markets Gvoke, a ready-to-use glucagon for severe hypoglycemia in children and adults; Keveyis for periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for endogenous hypercortisolemia in adults with Cushing’s syndrome. It is developing XP-8121, a weekly subcutaneous levothyroxine for hypothyroidism in Phase 3 trials. Incorporated 2005.
Company score
- Sentiment
- 0.33
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.45
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.16
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.25
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. John P. Shannon
- Founded2005
- Employees435
- Websitewww.xerispharma.com
Identifiers
- ISINUS98422E1038
- FIGIBBG012V1MG52
- CUSIP98422L107
- CIK0001346302